FULTON increases production capacity

By investing in the implementation of a third, fully automated production line, Fulton will increase annual production capacity by 60 million suppositories/ovules from 2026.

Fulton Medicinali, announces the introduction of a third production line for suppositories and ovules. An important step to meet growing demand in an expanding market. This new production line, designed with state-of-the-art technology, marks another significant milestone for the company in its ongoing mission to innovate and care for patients’ therapeutic needs.

Fulton Medicinali will integrate a highly automated facility into its production, reducing energy consumption and improving the efficiency of the manufacturing process. The new line is designed to respond quickly to market needs while ensuring a high standard of quality and safety. Furthermore it will allow the company to increase its production capacity by 60 million suppositories/ovules by 2026. The company is not stopping here: the introduction of the third production line is only the beginning of an expansion plan that will also include new developments in research and production.